Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Lynkuet

PharmaDeviceNews Lynkuet

Editorial infographic highlighting AbCellera’s ABCL635 programme, featuring an antibody graphic, laboratory visuals and symptom-tracking charts, with key points on an 83% reduction in hot flashes, upcoming safety results, new symptom data and the open question of durability.

Pharma & Biotech

One ABCL635 injection cut hot flashes by 83%. Can AbCellera prove the benefit lasts?

by Pallavi Madhiraju
October 12, 2026
0 Comments

AbCellera will reveal new ABCL635 safety and symptom data after reporting an 83% hot flash reduction. Can its antibody sustain the benefit?

Read More

Latest news and features

Johnson & Johnson reports long-term ICOTYDE efficacy and safety in plaque psoriasis
Eli Lilly’s TOGETHER-PsO trial links obesity treatment with psoriasis improvement
Perceive Biotherapeutics completes VOY-101 Phase 2a JOURNEY enrollment in geographic atrophy
Why Thermedical’s Durablate catheter could address difficult-to-reach heart arrhythmias
Kyowa Kirin Poteligeo MINT study shows 62.4% response in cutaneous T-cell lymphoma
Artemis Care Compass and AiVA bring AI-powered workflow tools to fertility clinics
How Lux Infusion plans to improve Qfitlia access and treatment coordination
BioMarin seeks FDA approval for Voxzogo in hypochondroplasia after Phase 3 success
Can SurGenTec’s Vantage system reduce surgical instrumentation and sterilisation requirements?
AviadoBio AVB-101 shows 90% progranulin increase in Phase 1/2 ASPIRE-FTD trial
AnX Robotica highlights 133-patient ARTIC study supporting ProScan AI performance
Celltrion presents LIBERTY-CD and LIBERTY-UC post hoc findings at ACG 2026

POPULAR NEWS

Representative image of a clinician reviewing skeletal imaging, illustrating Mirum Pharmaceuticals and Incyte’s zilurgisertib Phase 2 progress in fibrodysplasia ossificans progressiva and the rare disease treatment questions facing regulators.

Pharma & Biotech

Why Mirum Pharmaceuticals and Incyte’s zilurgisertib data could reset expectations in FOP treatment

June 15, 2026

Niagen Bioscience’s NB4168 has secured U.S. FDA Rare Pediatric Disease and European orphan designations as the company advances the experimental ataxia telangiectasia therapy toward human trials. Representative image.

Pharma & Biotech

Niagen wins twin rare-disease designations, but can NB4168 turn nicotinamide riboside evidence into a medicine?

July 14, 2026

Representative image of biopharma laboratory research. Gilead Sciences and Merck’s latest Phase 3 updates highlight the promise of once-weekly HIV treatment with islatravir and lenacapavir, while raising fresh questions over Trodelvy’s lung cancer expansion strategy.

Pharma & Biotech

Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology

June 9, 2026

Latest business and industry news

Elevra secures a major LG lithium contract, but why does pricing remain the biggest risk?
Stakk (ASX: SKK) posts 16.5% quarterly revenue growth after ParaScript acquisition
Frasers saved more than 1,000 Harvey Nichols jobs. Why are closures starting only weeks later?
Krystal plans 10,000 jobs across India. Can margins keep pace with such rapid workforce expansion?
CEMEX is saving $475m globally. What does the Lyons workforce cut reveal about its asset strategy?

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.